N‐terminal acetylation of α‐synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer
暂无分享,去创建一个
Sheena E Radford | J. Baum | A. Ashcroft | Lijuan Kang | Jean Baum | Gina M Moriarty | Lucy A Woods | Alison E Ashcroft | L. A. Woods | G. M. Moriarty | Lijuan Kang | S. Radford
[1] P. Axelsen,et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. , 2005, The Journal of biological chemistry.
[2] Adam J. Trexler,et al. N‐terminal acetylation is critical for forming α‐helical oligomer of α‐synuclein , 2012, Protein science : a publication of the Protein Society.
[3] David S Wishart,et al. RefDB: A database of uniformly referenced protein chemical shifts , 2003, Journal of biomolecular NMR.
[4] J. Baum,et al. Detection of transient interchain interactions in the intrinsically disordered protein alpha-synuclein by NMR paramagnetic relaxation enhancement. , 2010, Journal of the American Chemical Society.
[5] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[6] Michael A. Geeves,et al. Targeted Amino-Terminal Acetylation of Recombinant Proteins in E. coli , 2010, PloS one.
[7] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[8] F. Sherman,et al. Nα-terminal Acetylation of Eukaryotic Proteins* , 2000, The Journal of Biological Chemistry.
[9] D. Eliezer,et al. NMR mapping of copper binding sites in alpha-synuclein. , 2006, Biochimica et biophysica acta.
[10] Oleg Jardetzky,et al. Probability‐based protein secondary structure identification using combined NMR chemical‐shift data , 2002, Protein science : a publication of the Protein Society.
[11] L. Bubacco,et al. Interaction Between α-Synuclein and Metal Ions, Still Looking for a Role in the Pathogenesis of Parkinson’s Disease , 2009, NeuroMolecular Medicine.
[12] M. Vendruscolo,et al. The A53T mutation is key in defining the differences in the aggregation kinetics of human and mouse α-synuclein. , 2011, Journal of the American Chemical Society.
[13] J. Marsh,et al. Sensitivity of secondary structure propensities to sequence differences between α‐ and γ‐synuclein: Implications for fibrillation , 2006 .
[14] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[15] R. L. Baldwin,et al. Determination of free energies of N-capping in alpha-helices by modification of the Lifson-Roig helix-coil therapy to include N- and C-capping. , 1994, Biochemistry.
[16] H. Lashuel,et al. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.
[17] J. Marsh,et al. Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation. , 2006, Protein science : a publication of the Protein Society.
[18] Wei Wang,et al. A soluble α-synuclein construct forms a dynamic tetramer , 2011, Proceedings of the National Academy of Sciences.
[19] C. Griesinger,et al. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[20] Paul H. Axelsen,et al. The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.
[21] Jennifer C. Lee,et al. α-Synuclein: Stable compact and extended monomeric structures and pH dependence of dimer formation , 2004, Journal of the American Society for Mass Spectrometry.
[22] Vladimir N Uversky,et al. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. , 2009, Current protein & peptide science.
[23] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[24] S. Doglia,et al. Compact conformations of α‐synuclein induced by alcohols and copper , 2011, Proteins.
[25] V. Uversky,et al. Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: Conformational heterogeneity of α‐synuclein , 2009, Proteins.
[26] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[27] T. Arnesen. Towards a Functional Understanding of Protein N-Terminal Acetylation , 2011, PLoS biology.
[28] J Q Trojanowski,et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.
[29] Anders Wallin,et al. Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method , 2011, Neurochemical Research.
[30] R. L. Baldwin,et al. Further studies of the helix dipole model: Effects of a free α‐NH3+ or α‐COO− group on helix stability , 1989 .
[31] R. Aurora,et al. Helix capping , 1998, Protein science : a publication of the Protein Society.
[32] S. Radford,et al. Elongated oligomers in β2-microglobulin amyloid assembly revealed by ion mobility spectrometry-mass spectrometry , 2010, Proceedings of the National Academy of Sciences.
[33] D. Schwarzer,et al. Simultaneous detection of protein phosphorylation and acetylation by high-resolution NMR spectroscopy. , 2010, Journal of the American Chemical Society.
[34] R. L. Baldwin,et al. Helix capping propensities in peptides parallel those in proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. L. Baldwin,et al. Further studies of the helix dipole model: effects of a free alpha-NH3+ or alpha-COO- group on helix stability. , 1989, Proteins.
[36] D. Eliezer,et al. Residual structure, backbone dynamics, and interactions within the synuclein family. , 2007, Journal of molecular biology.
[37] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[38] D. Selkoe,et al. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.
[39] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] Bernard Schneider,et al. α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.
[41] D. Eliezer,et al. Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.
[42] F. Sherman,et al. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. , 2003, Journal of molecular biology.
[43] C. Griesinger,et al. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. , 2008, Journal of the American Chemical Society.
[44] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[45] Carlo Camilloni,et al. Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts. , 2012, Biochemistry.